REED - Revista Española de Enfermedades Digestivas

New issue alert	Contact
Submit a manuscript	Follow REEDigestivas_
Versión en español

Year 2015 / Volume 107 / Number 10
Original

Impact of the age of diagnosis on the natural history of ulcerative colitis

614-621

DOI: 10.17235/reed.2015.3736/2015

Tiago Cúrdia Gonçalves, Francisca Dias de Castro, Joao Firmino Machado, Maria Joao Moreira, Bruno Rosa, José Cotter,

Abstract

Background: Ulcerative colitis (UC) has a recognized phenotypic heterogeneity. Some studies suggest that age at diagnosis may influence features and natural history of the disease. Aim: This study aimed to compare patients’, disease’s and treatment’s features between Portuguese patients diagnosed before and after the age of 40-years-old. Methods: Retrospective single-center study that included 310 patients with UC, divided in two groups: Those diagnosed before the age of 40-years-old (early onset UC) and those diagnosed later than that (late onset UC). In each group features of the patients (gender, family history, smoking), of the disease (duration, extension, severity, clinical course, hospitalization, extraintestinal manifestations), and of treatment (oral aminosalicylates, systemic steroids or immunomodulators) were analyzed. Statistical analysis was performed using SPSSv22.0. Univariate and multivariate analyses were performed to assess factors associated with early and late onset UC. Results: From the analyzed patients, 207 had UC diagnosed before the age of 40 years old (43.5% men; mean age at diagnosis 29.4 ± 6.9 years) and 103 were diagnosed after that age (61.2% men; mean age at diagnosis 51.8 ± 8.1 years). In the group diagnosed before 40 years old, female gender (p = 0.003), severe disease (p = 0.002), chronic intermittent clinical course (p = 0.026), and hospitalizations (p = 0.001) were significantly more frequent. The use of oral aminosalicylates (p = 0.032), systemic steroids (p = 0.003) and immunomodulators (p = 0.012) were also more common in the early onset UC group. No differences between groups were found in family history, smoking, disease’s extension, extraintestinal manifestations, and use of biological agents. Multivariate analysis pointed early onset UC to be significantly associated with female gender (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.08-2.91; p = 0.024), chronic intermittent symptoms (OR, 2.34; 95% CI, 1.17-4.70; p = 0.016), and need of hospitalization (OR, 2.89; 95% CI, 1.46-5.72; p = 0.002). Conclusions: When diagnosed before the age of 40-yearsold, UC preferably affects women and manifests as a more severe disease, with more frequent hospitalizations and chronic intermittent symptoms. These facts might have implications in planning timely and individualized future therapeutic strategies.

New comment

Comments

01/03/2023 3:48:56
Golden State Urology Stockton
3133 Ԝ Marϲh Ln Suite 1040B,
Stockton, ᏟA 95219, United Stаtеs
+12094643627
hоw much does іt cost to get a vaeectomy reversed

References

1. Podolsky DK. Inflammatory bowel disease. The New England journal of medicine. 2002;347(6):417-29.

DOI: 10.1056/NEJMra020831

2. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39(5):690-7.

DOI: 10.1136/gut.39.5.690

3. Tragnone A, Corrao G, Miglio F, Caprilli R, Lanfranchi GA. Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). International journal of epidemiology. 1996;25(5):1044-52.

DOI: 10.1093/ije/25.5.1044

4. Azevedo LF, Magro F, Portela F, Lago P, Deus J, Cotter J, et al. Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach. Pharmacoepidemiology and drug safety. 2010;19(5):499-510.

DOI: 10.1002/pds.1930

5. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785-94.

DOI: 10.1053/j.gastro.2011.01.055

6. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54 e42; quiz e30.

DOI: 10.1053/j.gastro.2011.10.001

7. Ha CY, Newberry RD, Stone CD, Ciorba MA. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2010;8(8):682-7 e1.

DOI: 10.1016/j.cgh.2010.03.022

8. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504-17.

DOI: 10.1053/j.gastro.2004.01.063

9. Carr N, Schofield PF. Inflammatory bowel disease in the older patient. The British journal of surgery. 1982;69(4):223-5.

DOI: 10.1002/bjs.1800690418

10. Zimmerman J, Gavish D, Rachmilewitz D. Early and late onset ulcerative colitis: distinct clinical features. Journal of clinical gastroenterology. 1985;7(6):492-8.

DOI: 10.1097/00004836-198512000-00010

11. Riegler G, Tartaglione MT, Carratu R, D'Inca R, Valpiani D, Russo MI, et al. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). Digestive diseases and sciences. 2000;45(3):462-5.

DOI: 10.1023/A:1005424603085

12. Hadithi M, Cazemier M, Meijer GA, Bloemena E, Felt-Bersma RJ, Mulder CJ, et al. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World journal of gastroenterology : WJG. 2008;14(20):3183-7.

DOI: 10.3748/wjg.14.3183

13. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2005;19 Suppl A:5A-36A.

14. Loftus EV, Jr., Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Alimentary pharmacology & therapeutics. 2002;16(1):51-60.

DOI: 10.1046/j.1365-2036.2002.01140.x

15. Portela F, Magro F, Lago P, Cotter J, Cremers I, de Deus J, et al. Ulcerative colitis in a Southern European country: a national perspective. Inflammatory bowel diseases. 2010;16(5):822-9.

DOI: 10.1002/ibd.21119

16. Barreiro-de Acosta M, Magro F, Carpio D, Lago P, Echarri A, Cotter J, et al. Ulcerative colitis in northern Portugal and Galicia in Spain. Inflammatory bowel diseases. 2010;16(7):1227-38.

DOI: 10.1002/ibd.21170

17. Solberg IC, Lygren I, Jahnsen J, Aadland E, Hoie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scandinavian journal of gastroenterology. 2009;44(4):431-40.

DOI: 10.1080/00365520802600961

18. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. Journal of Crohn's & colitis. 2012;6(10):965-90.

DOI: 10.1016/j.crohns.2012.09.003

19. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. The American journal of gastroenterology. 2006;101(6):1274-82.

DOI: 10.1111/j.1572-0241.2006.00552.x

20. Loftus CG, Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, 3rd, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflammatory bowel diseases. 2007;13(3):254-61.

DOI: 10.1002/ibd.20029

21. Ott C, Obermeier F, Thieler S, Kemptner D, Bauer A, Scholmerich J, et al. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. European journal of gastroenterology & hepatology. 2008;20(9):917-23.

DOI: 10.1097/MEG.0b013e3282f97b33

22. Matsumoto S, Miyatani H, Yoshida Y. Ulcerative colitis: comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease. Digestive diseases and sciences. 2013;58(5):1306-12.

DOI: 10.1007/s10620-012-2517-5

23. Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63(3):423-32.

DOI: 10.1136/gutjnl-2012-303864

24. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, Tilloy E, Brazier F, Merle V, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. The American journal of gastroenterology. 2009;104(8):2080-8.

DOI: 10.1038/ajg.2009.177

25. Regueiro M, Kip KE, Cheung O, Hegazi RA, Plevy S. Cigarette smoking and age at diagnosis of inflammatory bowel disease. Inflammatory bowel diseases. 2005;11(1):42-7.

DOI: 10.1097/00054725-200501000-00006

26. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749-53.

DOI: 10.1136/gut.2005.082909

27. Kalkan IH, Dagli U, Oztas E, Tunc B, Ulker A. Comparison of demographic and clinical characteristics of patients with early vs. adult vs. late onset ulcerative colitis. European journal of internal medicine. 2013;24(3):273-7.

DOI: 10.1016/j.ejim.2012.12.014

28. Sarlos P, Kovesdi E, Magyari L, Banfai Z, Szabo A, Javorhazy A, et al. Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature. World journal of gastrointestinal pathophysiology. 2014;5(3):304-21.

29. Ruel J, Ruane D, Mehandru S, Gower-Rousseau C, Colombel JF. IBD across the age spectrum: is it the same disease? Nature reviews Gastroenterology & hepatology. 2014;11(2):88-98.

DOI: 10.1038/nrgastro.2013.240

30. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clinic proceedings. 2006;81(11):1462-71.

DOI: 10.4065/81.11.1462

31. Hoie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. The American journal of gastroenterology. 2007;102(8):1692-701.

DOI: 10.1111/j.1572-0241.2007.01265.x

32. Bringiotti R, Ierardi E, Lovero R, Losurdo G, Di Leo A, Principi M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World journal of gastrointestinal pathophysiology. 2014;5(4):550-9.

DOI: 10.4291/wjgp.v5.i4.550

33. Chen WX, Ren LH, Shi RH. Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World journal of gastroenterology : WJG. 2014;20(42):15657-63.

DOI: 10.3748/wjg.v20.i42.15657

34. Quezada SM, Cross RK. Association of age at diagnosis and ulcerative colitis phenotype. Digestive diseases and sciences. 2012;57(9):2402-7.

DOI: 10.1007/s10620-012-2081-z

35. Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. Journal of pediatric gastroenterology and nutrition. 2012;55(3):340-61.

DOI: 10.1097/MPG.0b013e3182662233

36. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. Journal of Crohn's & colitis. 2012;6(10):991-1030.

DOI: 10.1016/j.crohns.2012.09.002

37. Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. Journal of Crohn's & colitis. 2011;5(1):5-13.

DOI: 10.1016/j.crohns.2010.08.004

Letter

Broadening perspectives in the treatment of chronic pouchitis

DOI: 10.17235/reed.2024.10865/2024

Letter

Immuno-mediated colitis induced by nivolumab that mimics endoscopically and histologically an ulcerative colitis

DOI: 10.17235/reed.2024.10180/2023

Letter

An Epstein-Barr virus-positive mucocutaneous ulcer in a patient with ulcerative colitis: a recently described entity to take into account

DOI: 10.17235/reed.2024.10168/2023

Letter

Long-term remission achieved in a rare case of pyoderma gangrenosum and ulcerative colitis with surgery and postoperative infliximab

DOI: 10.17235/reed.2024.10144/2023

Letter

Ulcerative colitis induced by obinutuzumab in a patient treated for a follicular lymphoma

DOI: 10.17235/reed.2023.10009/2023

Letter

Effectiveness of 4 L, 2 L, and 1 L polyethylene glycol (PEG) bowel preparation for colonoscopy in patients with ulcerative colitis: a retrospective study

DOI: 10.17235/reed.2023.9979/2023

Original

Psychological disorders and coping strategies in patients with inflammatory bowel disease. Their impact on health-related quality of life

DOI: 10.17235/reed.2023.9935/2023

Letter

Is cervical dysplasia a major concern in females with inflammatory bowel disease? A Spanish retrospective study

DOI: 10.17235/reed.2023.9890/2023

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Original

Ulcerative colitis overall disease severity index predicts colectomy: a prospective cohort study

DOI: 10.17235/reed.2023.9754/2023

Letter

Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab

DOI: 10.17235/reed.2023.9745/2023

Original

Development and validation of a nomogram to predict non-response to 5-aminosalicylic acid in patients with ulcerative colitis

DOI: 10.17235/reed.2023.9703/2023

Letter

Extensive involvement of indolent T-cell lymphoma in a patient with ulcerative colitis

DOI: 10.17235/reed.2023.9623/2023

Letter

Iatrogenic rectal perforation due to application of topical treatment in a patient with ulcerative colitis: a rare complication

DOI: 10.17235/reed.2023.9599/2023

Original

Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis

DOI: 10.17235/reed.2023.9537/2023

Letter

Severe outbreak of ulcerative colitis and cerebral neoplasia. Difficult management in COVID time

DOI: 10.17235/reed.2023.9527/2023

Letter

Prediagnosis of soft tissue infection that was finally diagnosed as pyoderma gangrenosum of ulcerative colitis

DOI: 10.17235/reed.2022.9332/2022

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Letter

A rare case of ulcerative colitis following Bacillus Calmette-Guérin therapy

DOI: 10.17235/reed.2022.9191/2022

Letter

Ulcerative colitis complicated by autoimmune hepatitis-primary biliary cholangitis-primary sclerosing cholangitis overlap syndrome

DOI: 10.17235/reed.2022.9183/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Pyoderma gangrenosum in ulcerative colitis - An exuberant and painful complication

DOI: 10.17235/reed.2022.9120/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Letter

Dual biologic therapy for severe ulcerative colitis, concomitant extraintestinal manifestations and an orbital osteoma: a successful treatment

DOI: 10.17235/reed.2022.8964/2022

Letter

A rare case of an intestinal ulcer: AIDS and amebic colitis in a homosexual man with ulcerative colitis

DOI: 10.17235/reed.2022.8903/2022

Letter

One appendix too many: a severe IBD-U case in remission after appendectomy

DOI: 10.17235/reed.2022.8809/2022

Original

DOI: 10.17235/reed.2022.8668/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Original

Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia

DOI: 10.17235/reed.2022.8380/2021

Review

Adherence improvement in patients with ulcerative colitis: a multidisciplinary consensus document

DOI: 10.17235/reed.2021.8130/2021

Original

Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of the Epi-IBD 2011 study in the Vigo area

DOI: 10.17235/reed.2021.8003/2021

Letter

Influence of the onset of the SARS-CoV-2 pandemic on the diagnosis and treatment of ulcerative colitis

DOI: 10.17235/reed.2021.7768/2020

Original

Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study

DOI: 10.17235/reed.2021.7683/2020

Original

Thiopurine adherence: a high prevalence with low impact on UC outcomes

DOI: 10.17235/reed.2021.7630/2020

Letter

A case of severe diverticulosis in a patient with ulcerative colitis

DOI: 10.17235/reed.2020.7529/2020

Review

The use of contrast-enhanced ultrasound for chronic inflammatory bowel disease

DOI: 10.17235/reed.2020.7499/2020

Original

Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results

DOI: 10.17235/reed.2020.7472/2020

Original

Prevalence and factors associated with poor sleep quality in inflammatory bowel disease outpatients

DOI: 10.17235/reed.2020.7202/2020

Letter

Author´s answer to: “Effect of adacolumn® in ulcerative colitis with COVID-19”

DOI: 10.17235/reed.2020.7188/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Review

Vitamin D and inflammatory bowel disease: what do we know so far?

DOI: 10.17235/reed.2020.7061/2020

Original

Glasgow prognostic score is a predictive index for postoperative infectious complications after total proctocolectomy in ulcerative colitis patients

DOI: 10.17235/reed.2020.7047/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Original

Autoimmune sequential overlap syndrome (autoimmune hepatitis/primary sclerosing cholangitis) and inflammatory bowel disease: three clinical cases

DOI: 10.17235/reed.2020.6938/2020

Original

Meta-analysis of protein intake on the effect of Crohn’s disease and ulcerative colitis

DOI: 10.17235/reed.2020.6851/2019

Original

Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain

DOI: 10.17235/reed.2020.6847/2019

Original

Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?

DOI: 10.17235/reed.2020.6832/2019

Original

Predictive factors of clinical response to treatment with anti-TNF agents in ulcerative colitis: what have we learned from our patients?

DOI: 10.17235/reed.2020.6688/2019

Original

Association between autoimmune pancreatitis and ulcerative colitis: a report of 12 patients

DOI: 10.17235/reed.2020.6677/2019

Letter

Intra-abdominal desmoid tumor and chronic inflammatory bowel disease. An uncommon scenario

DOI: 10.17235/reed.2020.6648/2019

Original

Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohorts

DOI: 10.17235/reed.2020.6552/2019

Review

Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis

DOI: 10.17235/reed.2019.6336/2019

Original

Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease

DOI: 10.17235/reed.2019.6298/2019

Original

Differences in the need for adalimumab dose optimization between Crohn’s disease and ulcerative colitis

DOI: 10.17235/reed.2019.6148/2018

Case Report

Leukocytoclastic vasculitis after vaccination in a patient with inflammatory bowel disease

DOI: 10.17235/reed.2019.5963/2018

Letter

The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

DOI: 10.17235/reed.2019.5841/2018

Original

Vitamin D deficiency in outpatients with inflammatory bowel disease: prevalence and association with clinical-biological activity

DOI: 10.17235/reed.2018.5714/2018

Original

The association between de novo inflammatory bowel disease and celiac disease

DOI: 10.17235/reed.2019.5535/2018

Original

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

DOI: 10.17235/reed.2018.5368/2017

Original

Using the internet to evaluate the opinion of patients with inflammatory bowel disease with regard to the available information

DOI: 10.17235/reed.2018.5331/2017

Case Report

Serrated polyposis syndrome associated with long-standing inflammatory bowel disease

DOI: 10.17235/reed.2017.5068/2017

Case Report

Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis

DOI: 10.17235/reed.2017.5024/2017

Letter to the Editor

Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis

DOI: 10.17235/reed.2017.4941/2017

Original

Medium to long-term efficacy and safety of oral tacrolimus in moderate to severe steroid refractory ulcerative colitis

DOI: 10.17235/reed.2017.4899/2017

Original

Knowledge of disease and access to a specialist reported by Spanish patients with ulcerative colitis. UC-LIFE survey

DOI: 10.17235/reed.2017.4748/2016

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Original

What is the real-life maintenance mesalazine dose in ulcerative colitis?

DOI: 10.17235/reed.2016.4620/2016

Original

The concerns of Spanish patients with inflammatory bowel disease as measured by the RFIPC questionnaire

DOI: 10.17235/reed.2017.4621/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Original

The use of a segmental endoscopic score may improve the prediction of clinical outcomes in acute severe ulcerative colitis

DOI: 10.17235/reed.2016.4470/2016

Original

Meta-analysis of the association between appendiceal orifice inflammation and appendectomy and ulcerative colitis

DOI: 10.17235/reed.2016.4176/2015

Digestive Diseases Image

All that glitters is not gold. A different cause for an "ulcerative colitis"

Letter to the Editor

Ulcerative colitis in a patient with common variable immunodeficiency: does the treatment differ from the routine?

DOI: 10.17235/reed.2016.4115/2015

Original

Initial experience with golimumab in clinical practice for ulcerative colitis

DOI: 10.17235/reed.2016.4068/2015

Original

Endoluminal calprotectin measurement in assessment of pouchitis and a new index of disease activity: a pilot study

DOI: 10.17235/reed.2016.4066/2015

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Editorial

INTENSIFICATION OF MAINTENANCE THERAPY WITH INFLIXIMAB IN ULCERATIVE COLITIS

DOI: 10.17235/reed.2015.3907/2015

Original

FREQUENCY, PREDICTORS, AND CONSEQUENCES OF MAINTENANCE INFLIXIMAB THERAPY INTENSIFICATION IN ULCERATIVE COLITIS

DOI: 10.17235/reed.2015.3804/2015

Citation tools

Cúrdia Gonçalves T, Dias de Castro F, Firmino Machado J, Moreira M, Rosa B, Cotter J, et all. Impact of the age of diagnosis on the natural history of ulcerative colitis. 3736/2015

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics

This article has received 1248 visits.
This article has been downloaded 21 times.

Statistics from Dimensions

Statistics from Plum Analytics

Publication history

Received: 17/02/2015

Accepted: 26/05/2015

Online First: 22/06/2015

Published: 25/09/2015

Article revision time: 91 days

Article Online First time: 125 days

Article editing time: 220 days

This article has been rated by 1 readers.

Reader rating:

Valora este artículo:

Submission and tracking of manuscripts

Instructions to authors

Submission and tracking

Home

Articles

Current issues

Previous issues

Cookie	Purpose	Expiration	Cookie type
ASP.NET_SessionId	Makes it possible to control traffic from the server to multiple users at the same time, identification and access as a user.	Logout / End of project	Session
cookiesDirective	Makes it possible to remember cookie settings.	Logout / End of project	Session
vercookies	Makes it possible to display the notice on the use of cookies.	Logout / End of project	Session

Download to a citation manager

Statistics from Dimensions

Statistics from Plum Analytics

Submission and tracking of manuscripts

Receive the digital monthly newsletter of the REED

In accordance with current legislation, this publication is only for health care professionals.